Brief Title
Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Official Title
Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT
Brief Summary
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.
Study Type
Observational
Primary Outcome
Uptake of FDGal
Condition
Hepatocellular Carcinoma
Intervention
Measuring liver function by PET/CT
Study Arms / Comparison Groups
Liver tumors
Description: Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
14
Start Date
June 2010
Completion Date
April 2016
Primary Completion Date
April 2016
Eligibility Criteria
Inclusion Criteria: - liver tumor - referred for stereotactic radiation therapy - age > 18 years Exclusion Criteria: - Impaired kidney function - Pregnancy
Gender
All
Ages
18 Years - 85 Years
Accepts Healthy Volunteers
No
Contacts
Morten Høyer, MD PhD, ,
Location Countries
Denmark
Location Countries
Denmark
Administrative Informations
NCT ID
NCT01213758
Organization ID
AarhusLiverRadGal
Responsible Party
Sponsor
Study Sponsor
University of Aarhus
Collaborators
Danish Cancer Society
Study Sponsor
Morten Høyer, MD PhD, Principal Investigator, Aarhus University Hospital
Verification Date
October 2017